# ChatGPT Review Record: ADCdb-Atlas-ADC AIDD Design v0.2 PR #86

- Review date: 2026-08-21 EDT
- Pull request: https://github.com/leezx/StelligenOS/pull/86
- Approved head: `93a8275db62c93222195417870b8373c29aeb12b`
- Base: `main@5b2fa3a`
- Merge commit: `ad92c5aaa02216e8d8342b9e9b124e0dc1658196`
- Reviewer: ChatGPT via the Chrome web conversation `ADC研发框架优化`
- GitHub source: explicitly selected in the ChatGPT composer
- Decision: `APPROVE`
- Record type: `direct_verbatim_review`
- Execution authorization: none

## GitHub facts verified by the reviewer

- PR open, non-draft and mergeable at review time;
- ahead 2, behind 0;
- exactly three changed files: canonical design, v0.2 handoff and worklog;
- design commit `fe1b6e7` plus metadata commit `93a8275`;
- CI run #115 completed successfully for Python 3.11 and 3.12, including unit
  tests, git-sync behavior, repository-boundary, no-bytecode and
  unchanged-worktree checks.

## Final decision, verbatim

> APPROVE
>
> 我没有发现阻断问题。
>
> PR #86 可以合并。

## Load-bearing findings accepted by the reviewer

The reviewer confirmed that approved v0.1 semantics remained intact:

- MSS/pMMR refractory mCRC territory-first entry;
- ADCdb remains blocked by `SRCADM-02` and precedent remains prior-only;
- crowding, target/antibody/epitope IP and linker-payload FTO remain separate;
- Stage 5 retains `PROVISIONAL_ADVANCE`, `EXPLORATION`, `HOLD`, `FAIL`;
- `ProgramCommitmentReview@0.2.0` and its asset-directed versus blocked
  downstream mapping remain unchanged.

The reviewer found that v0.2 closes the earlier evidence cycle as a DAG:

```text
Stage 7A AIDD design candidate
  -> human synthesis decision
Stage 7B experimental antibody-hit validation
  -> experimental ADC_GRADE_HIT
  -> human conjugation authorization
Stage 8 manufactured ADC
Stage 9 post-conjugation retention and efficacy validation
```

The reviewer specifically accepted that Stage 9A measures construct identity
and binding retention against the matched unconjugated binder, Stage 9B
measures post-conjugation delivery retention, and Stage 9C no longer duplicates
binding retention.

The minimum artifact fields were accepted as a projection floor rather than a
second authority. The reviewer noted that the self-review correctly retained
the canonical Stage 3/4 names and did not add a second T12 disposition, sponsor
route or Gate truth. The provenance envelope, failure/block/error separation,
unknown preservation and four cost-escalation decisions were also accepted.

## Non-blocking observations

1. `ADC_GRADE_HIT` must be defined by the future Stage 7 contract as a
   pipeline-local binder-qualification status, not a Gate disposition, Asset
   lifecycle state or global core-object status.
2. The future Stage 7 contract PR must choose the canonical epitope artifact
   name (`epitope_opportunities.tsv` / `epitope_packets/` versus the older
   design wording) because no authoritative contract exists yet.
3. If an asset-directed Program Commitment exists but only
   `aidd_execution_decision.json` is missing, a future contract may use a more
   precise operational blocker than `BLOCKED_NO_COMMITMENT`. This wording issue
   did not change the frozen commitment mapping and did not block the design.

## Approval boundary

The approval covers only the v0.2 design architecture: Stage 7A/7B
pre-assembly antibody qualification, minimum artifact projection schemas,
provenance envelope, failure taxonomy and four human cost-escalation
checkpoints.

It does not authorize Stage 0 source admission, ADCdb retrieval/parsing, Atlas
analysis, Gate execution, target ranking, AIDD, synthesis, antibody testing,
conjugation, ADC manufacture, CRO/wet-lab, in-vivo work, or any external DATA
run.

